Literature DB >> 15769638

Pathological features of NASH.

Elizabeth M Brunt1, Dina G Tiniakos.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a term currently applied to accumulation of triglycerides in the liver which is observed microscopically as "macrovesicular" steatosis. The term applies to the full range of liver parenchymal injury from "simple steatosis" to "steatohepatitis" with or without fibrosis. This article discusses the full histopathologic spectrum of NAFLD. Additionally, the summary includes an historical overview as well as contemporary thoughts on the significance of the process(es). While largely focused on adult NAFLD, the manuscript also summarizes what has been reported to date for NAFLD in the pediatric population.

Entities:  

Mesh:

Year:  2005        PMID: 15769638     DOI: 10.2741/1632

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  17 in total

Review 1.  Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease.

Authors:  Andrea Tannapfel; Helmut Denk; Hans-Peter Dienes; Cord Langner; Peter Schirmacher; Michael Trauner; Berenike Flott-Rahmel
Journal:  Virchows Arch       Date:  2011-03-26       Impact factor: 4.064

2.  Hepatic pathology among patients without known liver disease undergoing bariatric surgery: observations and a perspective from the longitudinal assessment of bariatric surgery (LABS) study.

Authors:  David E Kleiner; Paul D Berk; Jesse Y Hsu; Anita P Courcoulas; David Flum; Saurabh Khandelwal; John Pender; Alfons Pomp; James Roerig; Laura L Machado; Bruce M Wolfe; Steven H Belle
Journal:  Semin Liver Dis       Date:  2014-04-29       Impact factor: 6.115

Review 3.  [Steatohepatitis after chemotherapy for colorectal liver metastases (CASH)].

Authors:  A Tannapfel; A Reinacher-Schick; B Flott-Rahmel
Journal:  Pathologe       Date:  2011-07       Impact factor: 1.011

4.  Anti-inflammatory effect of insulin in the human hepatoma cell line HepG2 involves decreased transcription of IL-6 target genes and nuclear exclusion of FOXO1.

Authors:  Emelie Wallerstedt; Madeléne Sandqvist; Ulf Smith; Christian X Andersson
Journal:  Mol Cell Biochem       Date:  2011-02-05       Impact factor: 3.396

5.  An apoptosis panel for nonalcoholic steatohepatitis diagnosis.

Authors:  Tarek I Abu-Rajab Tamimi; Hesham M Elgouhari; Naim Alkhouri; Lisa M Yerian; Michael P Berk; Rocio Lopez; Phillip R Schauer; Nizar N Zein; Ariel E Feldstein
Journal:  J Hepatol       Date:  2011-02-12       Impact factor: 25.083

6.  Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients.

Authors:  Dima L Diab; Lisa Yerian; Philip Schauer; Sangeeta R Kashyap; Rocio Lopez; Stanley L Hazen; Ariel E Feldstein
Journal:  Clin Gastroenterol Hepatol       Date:  2008-07-26       Impact factor: 11.382

7.  The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk.

Authors:  Naim Alkhouri; Tarek Abu-Rajab Tamimi; Lisa Yerian; Rocio Lopez; Nizar N Zein; Ariel E Feldstein
Journal:  Dig Dis Sci       Date:  2009-12-05       Impact factor: 3.199

Review 8.  Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal.

Authors:  Naim Alkhouri; Laura J Dixon; Ariel E Feldstein
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2009-08       Impact factor: 3.869

9.  Silymarin prevents palmitate-induced lipotoxicity in HepG2 cells: involvement of maintenance of Akt kinase activation.

Authors:  Zhenyuan Song; Ming Song; David Y W Lee; Yanze Liu; Ion V Deaciuc; Craig J McClain
Journal:  Basic Clin Pharmacol Toxicol       Date:  2007-10       Impact factor: 4.080

Review 10.  [Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Grade 2 consensus-based guidelines].

Authors:  A Tannapfel; H Denk; H P Dienes; C Langner; P Schirmacher; M Trauner; B Flott-Rahmel
Journal:  Pathologe       Date:  2010-05       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.